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Abstract
Although etiological studies have shown genetic disorders to be a common cause of congenital/early-onset sensorineural
hearing loss, there have been no detailed multicenter studies based on genetic testing. In the present report, 264 Japanese
patients with bilateral sensorineural hearing loss from 33 ENT departments nationwide participated. For these patients, we
first applied the Invader assay for screening 47 known mutations of 13 known deafness genes, followed by direct
sequencing as necessary. A total of 78 (29.5%) subjects had at least one deafness gene mutation. Mutations were more
frequently found in the patients with congenital or early-onset hearing loss, i.e., in those with an awareness age of 0–6
years, mutations were significantly higher (41.8%) than in patients with an older age of awareness (16.0%). Among the 13
genes, mutations in GJB2 and SLC26A4 were mainly found in congenital or early-onset patients, in contrast with
mitochondrial mutations (12S rRNA m.1555A.G, tRNA(Leu(UUR)) m.3243A.G), which were predominantly found in older-
onset patients. The present method of simultaneous screening of multiple deafness mutations by Invader assay followed by
direct sequencing will enable us to detect deafness mutations in an efficient and practical manner for clinical use.
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Introduction
From a series of etiological studies, 60–70% of childhood hearing
loss has been estimated to be of genetic etiology, with the rest due to
environmental causes, including newborn delivery trouble, acoustic
trauma, ototoxic drug use, and prenatal/postnatal infection [1].
However, until now, there has been no multicenter study based on
genetic testing. Along with early discovery of hearing loss by
newborn hearing screening programs and subsequent intervention
programs, much attention has been paid to the determination of the
hearing loss etiology. Therefore, genetic testing has become more
important for highly accurate diagnosis, prediction of severity of
hearing loss, estimation of associated abnormalities, selection of
appropriate habilitation options, prevention of hearing loss, and
better genetic counseling. Although more than one hundred loci
have been mapped and 46 genes reported to be responsible for
hereditary hearing loss (Hereditary Hearing Homepage; http://
webh01.ua.ac.be/hhh/), many may cause similar phenotypes
without any abnormality other than hearing loss. This genetic
heterogeneity has made clinical application difficult, in spite of the
considerable advances in discovery of deafness genes. We have
previously established a screening strategy focusing on recurrent
mutations and demonstrated its benefits for clinical application [2].
We carried out the current multicenter study to determine 1)
whether the simultaneous screening of the multiple deafness
mutations by Invader assay is applicable for clinical use, 2) whether
the genetic etiology is truly prevalent among hearing loss patients
and 3) whether genetic causes differ by ages.
Materials and Methods
Subjects and clinical status
As summarized in Table 1, two hundred sixty-four Japanese
patients with bilateral sensorineural hearing loss from 33 ENT
departments nationwide participated in the present study. We first
applied the Invader assay for screening forty-seven known
mutations of 13 known deafness genes, followed by direct
sequencing as necessary.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31276Hearing loss was evaluated using pure-tone audiometry (PTA)
classifiedbya pure-toneaverage over 500, 1000,2000 and4000 Hz
in the betterhearing ears. Forchildren who were unable to be tested
by PTA, we used an average over 500, 1000, 2000 Hz in either
auditory steady-stem response (ASSR) or conditioned oriented
reflex audiometry (COR), or the response threshold (dB) from
auditory brainstem response (ABR). Computed tomography (CT)
scans were performed to check for congenital inner ear anomalies.
Status of hearing loss in the 264 patients was: mild (21–40 dB)
in 39 patients (14.7%), moderate (41–70 dB) in 84 (31.8%), severe
(71–94 dB) in 39 (14.8%) and profound (.95 dB) in 56 patients
(21.2%). Twenty-four subjects were classified as having normal
hearing due to a specific audiogram with hearing loss only in the
high or low frequency portions. With regard to onset age (the age
of awareness), 141 patients had early onset deafness (below 6 y.o.),
100 had late onset deafness, and the rest had unknown onset ages.
The inheritance composition of the subjects was as follows: 38
subjects from autosomal dominant or mitochondrial inherited
families (two or more generations affected); 119 subjects from
autosomal recessive families (parents with normal hearing and two
or more affected siblings) or subjects with sporadic deafness (also
compatible with recessive inheritance or non-genetic hearing loss).
None of the patients had an X-linked pattern of inheritance. The
numbers of patients with other manifestations were inner ear
malformations (52), enlarged vestibular aqueduct (EVA) (30),
goiter (8), and diabetes mellitus (14). None of the patients had
typical clinical features of Usher syndrome or BOR syndrome.
All subjects gave prior informed consent for participation in the
project and the Ethical Committee of Shinshu University as well as
the relevant bodies of the participating institutions of the Deafness
Gene Study Consortium approved the study.
Invader assay
Invader technology is convenient for mutation genotyping,
offering a simple diagnostic platform to detect single nucleotide
changes with high specificity and sensitivity from unamplified
genomic DNA.
We applied the Invader assay for screening forty-seven known
mutations of 13 known deafness genes [GJB2(NM_004004.5),
SLC26A4(NM_000441.1), COCH(NM_001135058.1), KCNQ4(NM_
172163.2), MYO7A(NM_000260.3), TECTA(NM_005422.2), CRYM
(NM_001888.3), POU3F4(NM_000307.3), EYA1(NM_172060.2), mi-
tochondrial 12 s ribosomal RNA, mitochondrial tRNA(Leu), mito-
chondrial tRNA(Ser), and mitochondrial tRNA(Lys)] (Table 2).
Mutations were selected on the basis of a mutation/gene database
established in the Japanese deafness population. The detailed
methodological protocol was described elsewhere [2]. In brief, 1.2 ul
of primary probe/Invader oligonucleotides mixture (containing
0.5 umol/l wild type primary probes, 0.5 umol/l mutant primary
probe, 0.05 umol/l Invader oligonucleotide, and 10 mmol/l MOPS)
were poured into each well of 384-well plates. Fluorescent resonance
energy transfer (FRET)/Cleavase mixture (Third Wave Technologies,
Madison, WI) was added to the probe/Invader oligonucleotide-
containing plates. Then, 3 ul of 5–100 fmol/l synthetic target
oligonucleotides (positive control), 10 ug/ml yeast tRNA (no target
control), and denatured genomic DNA samples (.15 ng/ul) were
added. Next, 6 ul of mineral oil (Sigma, St. Louis, MO) were overlayed
into all reaction wells and incubated at 63uC for 4 hour. After
incubation fluorescence was measured by a Cyto Fluor 4000
fluorescent micro plate reader (Applied Biosystems, Foster CA). The
heteroplasmy rate for mitochondrial mutations was quantified by
detection of fluorescently labeled and digested PCRproducts through a
fluorescence imaging system [2].
Direct sequencing
Dominant mutations and mitochondrial mutations are them-
selves diagnostic criteria for molecular diagnosis. But a hallmark of
recessive mutations, in GJB2 and SLC26A4 for example, is the
detection of two mutations in the paternal and maternal alleles. In
this study, direct sequencing was further carried out as follows: 1)
GJB2 mutation analysis for all subjects, because the authors
wanted to clarify whether the number of mutations on the invader
panel are enough (saturated) or not. 2) SLC26A4 mutation analysis
for all the subjects with EVA, 3) SLC26A4 mutation analysis for
heterozygous patients for these genes. DNA fragments containing
the entire coding region were sequenced as described elsewhere
[3,4].
Results
The mutations found by Invader assay and direct sequencing in
this study are summarized in Table 2 and 3.
Invader Assay
A total of 74 (28.0%) hearing-impaired subjects (n=264) were
found to have at least one deafness gene mutation. Among the
deafness genes situated on the present diagnostic panel, mutations
were most frequently found in the GJB2 gene. Screening of GJB2
showed mutations of one or both alleles of the gene in 43 (43/264;
16.2%) samples from the subjects, of which 13 cases had only a
single mutation, and 30 cases were compound heterozygotes or
homozygotes, confirmed by segregation analysis (Table 4). The
most common mutation was c.235delC, accounting for nearly
67% (29/43) of all GJB2 mutated patients. On the other hand, the
GJB2: c.35delG mutation, which is known to be the most common
mutation in Caucasian or other ethnic populations, was not found
in this group. The second most common group of GJB2 mutations
consisted of p.[G45E; Y136X], p.V37I, and c.299_300del. These
mutations were detected in more than 5 patients each, and their
allele frequencies were relatively high. Three mutations (p.T86R,
p.R143W, and c.176_191del) were observed in more than one
Table 1. Clinical features of subjects in this study.
Total
(n=264)
Early onset
(n=141)
Late onset
(n=100)
Severity of HL
normal – moderate 148 58 78
severe – profound 95 70 21
unknown 21 13 1
Inheritance
AD or Mitochondrial 38 9 24
AR or Sporadic 119 69 42
unknown 107 63 34
Other clinical features
inner ear malformations 52 37 10
EVA 30 22 4
goiter 8 4 3
diabetes mellitus 14 3 11
HL: Hearing loss.
AD: Autosomal dominant.
AR: Autosomal recessive.
EVA: Enlarged vestibular aqueduct.
doi:10.1371/journal.pone.0031276.t001
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Gene Exon Codon location Nucleotide change
Frequency of mutant
alleles (n=528)
Number of patients with
mutations (n=264)
GJB2 exon 2 p.L79fs c.235delC 43 (8.1%) 29 (10.9%)
GJB2 exon 2 p.V37I c.109G.A 7 (1.3%) 6 (2.3%)
GJB2 exon 2 p.[G45E; Y136X] c.[134G.A; 408C.A] 10 (1.9%) 10 (3.8%)
GJB2 exon 2 p.G59fs c.176_191del 3 (0.6%) 3 (1.1%)
GJB2 exon 2 p.R143W c.427C.T 4 (0.8%) 4 (1.5%)
GJB2 exon 2 p.H100fs c.299_300del 5 (0.9%) 5 (1.9%)
GJB2 exon 2 p.T123N c.368C.A 4 (0.8%) 4 (1.5%)
GJB2 exon 2 p.T86R c.257C.G 1 (0.2%) 1 (0.4%)
GJB2 exon 2 p.F191L c.570T.C0 0
GJB2 exon 2 p.I71T c.212T.C0 0
GJB2 exon 2 p.A49V c.146C.T0 0
GJB2 exon 2 p.G12fs c.35delG 0 0
SLC26A4 exon 19 p.H723R c.2168A.G 22 (4.1%) 17 (6.4%)
SLC26A4 int 7/exon 8 splice site c.919-2A.G 2 (0.4%) 2 (0.8%)
SLC26A4 exon 7 p.T410M c.1229C.T 4 (0.8%) 3 (1.1%)
SLC26A4 exon 7 p.V306fs c.917insG 0 0
SLC26A4 exon 19 p.T721M c.2162C.T0 0
SLC26A4 exon 8/int 8 splice site c.1001+1G.A0 0
SLC26A4 exon 9 p.A372V c.1115C.T0 0
SLC26A4 exon 5 p.M147V c.439A.G 1 (0.2%) 1 (0.4%)
SLC26A4 int 5/exon 6 splice site c.601-1G.A0 0
SLC26A4 exon 9 p.K369E c.1105A.G 1 (0.2%) 1 (0.4%)
SLC26A4 exon 15 p.S551fs c.1652insT 1 (0.2%) 1 (0.4%)
SLC26A4 exon 15 p.C565Y c.1693G.A0 0
SLC26A4 exon 17 p.S666F c.1997C.T0 0
SLC26A4 exon 19 p.E704fs 2111ins GCTGG 1 (0.2%) 1 (0.4%)
SLC26A4 exon 4 p.L108fs c.322delC 0 0
SLC26A4 exon 4 p.P123S c.367C.T0 0
SLC26A4 exon 10 p.N392Y c.1174A.T0 0
SLC26A4 exon 17 p.S610X c.1829C.A0 0
SLC26A4 exon 17 p.S657N c.1970G.A0 0
EYA1 exon 12 p.D396G c.1187A.G0 0
EYA1 exon 8 p.R264X c.790C.T0 0
EYA1 exon 7 p.Y193X c.579C.G0 0
COCH exon 5 p.A119T c.441G.A0 0
KCNQ4 exon 5 p.W276S c.827G.C0 0
MYO7A exon22 p.A886fs c.2656_2664del 0 0
TECTA exon 16 p.R1773X c.5318C.T0 0
TECTA exon 20 p.R2121H c.6063G.A0 0
Mitochondrial 12S rRNA m.1555A.G - 5 (1.9%)
Mitochondrial tRNALeu m.3243A.G - 6 (2.3%)
Mitochondrial tRNASer m.7445A.G- 0
Mitochondrial tRNALys m.8296 A.G- 0
CRYM exon 8 p.K314T c.941 A.C0 0
CRYM exon 8 p.X315Y c.945 A.T0 0
doi:10.1371/journal.pone.0031276.t002
Simultaneous Screening of Hearing Loss Mutations
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31276patient. p.F191L, p.I71T, p.A49V and c.35delG mutations were
not found. One pair of p.[G45E; Y136X] mutations was detected
among 10 persons in a heterozygous state. Subsequent parental
DNA segregation study through direct sequencing indicated two
mutations were in cis. The p.T123N mutation was found in 4
subjects but, based on our recent study, is not likely to be a
pathologic mutation [5].
The second most frequent gene with mutations was the SLC26A4
gene (23/264; 8.7%). Five cases were homozygotes of p.H723R,
one was a homozygote of p.T410M, 3 were compound heterozy-
gotes, and 14 had only one mutation of SLC26A4 (Table 4). Of the
19 SLC26A4 mutations, 12 (c.917insG, p.T721M, c.1001+1G.A,
p.A372V, c.601-1G.A, p.C565Y, p.S666F, c.322delC, p.P123S,
p.N392Y, p.S610X, and p.S657N) were not found in any samples,
but the remaining 7 SLC26A4 mutations were confirmed in more
than onesubject.Especially,thep.H723R mutationwas found tobe
in high allele frequency (4.1%). All of the patients with SLC26A4
mutations had EVA, which has been demonstrated to be a result of
the mutations of this gene. SLC26A4 mutations were detected by
Invader assay in 63.6% of the patients with EVA.
Mitochondrial m.1555A.G mutations were found in 1.9% (5/
264) of the patients and the m.3243A.G mutation was identified
in 2.3% (6/264).
Mutations in nine deafness genes (COCH, KCNQ4, MYO7A,
TECTA, CRYM, POU3F4, EYA1, mitochondrial tRNA(Lys)
m.8296A.G, mitochondrial tRNA(Ser) m.7445A.G) were not
identified in any patients (Table 2).
Notably, 4 subjects were found to have double gene mutations.
Two cases were SLC26A4 compound heterozygous or homozy-
gous mutations with a GJB2 heterozygous mutation. One case
was a compound heterozygous of GJB2 with a SLC26A4
heterozygous mutation and the remaining case was a GJB2
Table 3. Mutation list found by direct sequencing analysis.
Gene Exon Codon location Nucleotide change
Frequency of mutant
alleles (n=528)
Number of patients with
mutations (n=264)
GJB2 exon 2 p.T8M c.23C.G 1 (0.2%) 1 (0.4%)
GJB2 exon 2 p.K12fs c.35insG 1 (0.2%) 1 (0.4%)
GJB2 exon 2 p.F106Y c.317T.A 1 (0.2%) 1 (0.4%)
GJB2 exon 2 p.A171fs c.511insAACG 2 (0.4%) 2 (0.8%)
GJB2 exon 2 p.C174S c.522G.C 1 (0.2%) 1 (0.4%)
SLC26A4 exon 14 p.S532I c.1595G.T 2 (0.4%) 2 (0.8%)
SLC26A4 exon 16 p.R581S c.1743G.C 1 (0.2%) 1 (0.4%)
SLC26A4 exon 17 p.V659L c.1975G.C 2 (0.4%) 2 (0.8%)
SLC26A4 exon 10 p.L407fs c.1219delCT 1 (0.2%) 1 (0.4%)
SLC26A4 exon 15/int 15 splice site c.1931+5G .A 5 (0.9%) 4 (1.5%)
doi:10.1371/journal.pone.0031276.t003
Table 4. Diagnostic efficiency of Invader assay alone and Invader assay and direct sequencing.
Total (n=264) Early onset (n=141) Late onset (n=100)
Invader assay alone
GJB2 homozygote/compound heterozygote 30 (11.4%) 29 (20.6%) 1 (1.0%)
GJB2 heterozygote 13 (4.9%) 7 (5.0%) 6 (6.0%)
SLC26A4 homozygote/compound heterozygote 9 (3.4%) 9 (6.4%) 0 (0%)
SLC26A4 heterozygote 14 (5.3%) 10 (27.1%) 2 (2.0%)
Mitochondria A1555G 5 (1.9%) 2 (1.4%) 2 (2.0%)
Mitochondria A3243G 6 (2.2%) 1 (0.7%) 5 (5.0%)
Total 74 (28.0%)* 55 (39.0%)* 16 (16.0%)
Invader assay and direct sequencing
GJB2 homozygote/compound heterozygote 33 (12.5%) 31 (21.9%) 2 (2.0%)
GJB2 heterozygote 13 (4.9%) 7 (5.0%) 5 (5.0%)
SLC26A4 homozygote/compound heterozygote 18 (6.8%) 18 (12.7%) 0 (0%)
SLC26A4 heterozygote 7 (2.7%) 4 (2.8%) 2 (2.0%)
Mitochondria A1555G 5 (1.9%) 2 (1.4%) 2 (2.0%)
Mitochondria A3243G 6 (2.2%) 1 (0.7%) 5 (5.0%)
Total 78 (29.5%)** 59 (41.8%)** 16 (16.0%)
*Three cases carried double mutations (cases 1 to 3 in Table 5).
**Four cases carried double mutations shown in Table 5.
doi:10.1371/journal.pone.0031276.t004
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(Table 5).
The detection rate of mutations was 40.4% for the patients with
congenitalorearly-onsethearingloss,i.e.inthosewithanawareness
age of 0,6 years. The rate in congenital hearing loss patients also
increased when restricting to the patients with moderate or more
severe hearing loss (.50 dB; 40.7%) or severe hearing loss
(.70 dB; 44.3%) (Fig. 1). In contrast, the detection rate was only
16.0% in the patients with an older age of onset/awareness (Fig. 1).
Among the 13 included genes, mutations is GJB2 and SLC26A4
were mainly found in congenital patients or early-onset patients, in
contrast with mitochondrial mutations, such as 12S rRNA
m.1555A.G or tRNA(Leu(UUR)) m.3243A.G, which were
predominantly found in older-onset patients (Table 4). The
p.V37I mutation in the GJB2 gene was also found in older-onset
patients (data not shown).
With regard to the relationship between radiographic findings
and genetic testing, the mutation detection rate was elevated when
restricting to the patients with inner ear anomaly (50.0%) and
EVA (63.6%) (Fig. 2).
Direct sequencing
Direct sequencing identified 9 mutations in 15 cases which were
not included in the Invader assay panel and improved the mutation
detection/diagnostic rate obtained by Invader assay analysis
(28.0%/18.6%) to 29.5%/22.7%. (Fig. 1). Combining direct
sequencing with invader screening enhanced the diagnostic rate
notably but not the mutation detection rate. In detail, direct
sequencing identified additional mutations in three cases with single
GJB2 mutations by Invader assay that were finally diagnosed as
compound heterozygous mutations of GJB2 (p.[T86R]; c.[511in-
sAACG], p[T8M];[V37I] and c.[35insG];[235delC]).
In 7 cases only a single SLC26A4 mutation was found by invader
assay, and additional mutations were found by direct sequencing
(two cases of p.[H723R];c[1931+5G.A] and one each cases of
p.[R581S];[H723R], p.[V659L];[H723R], p.[S532I]; c.[2111insG-
CTGG], p.[T410M]; c.[1931+5G.A] and p.[K396E];[S532I]).
Twocases carried EVAbutwithout any mutationsfound inInvader
assay, c[1931+5G.A]; [1931+5G.A] and p.[V659L];c[1219
delCT] compound heterozygous mutations were found by direct
sequencing. With the combination of Invader assay and direct
sequencing, and restriction to patients with EVA, the mutation
detection rate was elevated to 17/22 cases (77.3%, Fig. 2). Fifteen of
them carried homozygous or compound heterozygous SLC26A4
mutations.
Discussion
We previously reported that simultaneous detection of
common deafness gene mutations has excellent sensitivity and
accuracy [2]. In this study, using samples from patients at 33
institutions nationwide from northern to southern Japan, we
confirmed that the Invader assay based on the Japanese deafness
gene mutation database works efficiently in the clinical base to
detect the responsible gene mutations from the patients with
Table 5. Double mutation cases found in simultaneous
mutation screening.
Genotype Patients Number
GJB2:p.[V37I];[V37I]; Mitochondria m.1555A.G 1 (0.4%)
GJB2:c.[235delC];p.[R143W]; SLC26A4:p.[M147V] 1 (0.4%)
GJB2:p.[V37I]; SLC26A4:p.[H723R];[ H723R] 1 (0.4%)
GJB2:p.[F106Y]; SLC26A4:p.[H723R]; c.[1931+5G.A] 1 (0.4%)
Total 4 (1.5%)
doi:10.1371/journal.pone.0031276.t005
Figure 1. Detection rate by onset/awareness age and severity of hearing loss. Diagnostic rates and detection rates of this simultaneous
multiple mutations screening and direct sequencing for biallelic mutations in autosominal recessive genes or mitochondrial mutations increased
when restricted to congenital/early-onset hearing loss, and moderate or severe hearing loss. Combined direct sequence and invader screening
enhanced the diagnostic rate but not the mutation detection rate.
doi:10.1371/journal.pone.0031276.g001
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overall, and the 41.8% detection rate for congenital or early onset
sensorineural hearing loss was especially remarkable. A series of
epidemiological studies have demonstrated that genetic disorders
are common causes of congenital deafness and it is estimated that
60–70% of the etiology may be caused by genetic factors [1].
Genetic testing is crucial to diagnose the etiology, but more than
100 genes are estimated to be involved and such genetic
heterogeneiety has hampered the genetic testing for deafness as
a routine clinical test. The present detection rate; i.e., 41.8%, is a
strikingly good rate for a clinical application, and it is expected
that clinical deafness mutation screening will greatly improve
medical management and facilitate extensive genetic counseling
for hearing impairment. Additional direct sequencing, as well as a
new version of the screening panel which includes novel identified
mutations, will likely improve the detection rate. For the older
ages of onset, the detection rate was comparatively low (16.0%).
Probably this is due to the panel mainly including responsible
genes for congenital deafness but not the responsible genes for
late onset hearing loss. An alternative explanation may be that
environmental factors may be involved in this group of deafness
patients.
The present study confirmed that mutations in three genes,
GJB2, SLC26A4, and the mitochondrial 12 s rRNA, are so far the
major known causes of hereditary hearing loss nationwide in
Japanese [6], and thus much attention should be paid to these
genes when performing genetic testing of hearing loss patients.
The most frequently found were mutations in the GJB2 gene.
This gene is so far the most common responsible gene for
congenital deafness worldwide [7]. The detection rates (17.4% for
all, 27.0% for congenital) are in accordance with our previous data
of 15% in the overall deafness population and 25% in congenital
deafness patients [5]. The mutation spectrum found in this study is
also in accordance with our previous results [2,4,5]. In GJB2
screening, 46 (17.4%) samples from deafness subjects had
mutations of one or both alleles of the GJB2 gene. As expected
from the above reports, the c.235delC mutation was found to be
the most prevalent mutation in our screening, accounting for
10.9% (29 of 264) of the hearing-impaired persons. Fourteen
patients were c.235delC homozygotes and 11 were compound
heterozygotes having c.235delC, confirmed by segregation anal-
ysis, and 4 patients were c.235delC heterozygotes without a second
mutation. Direct sequencing identified novel mutations (p.T8M,
c.35insG, p.F106Y, p.C174S and c.512insAACG) in the patients
with a single mutation detected by Invader assay (Table 3).
Many benefits of GJB2 gene genetic testing have been pointed
out. There have been general rules that inactivating mutations
(deletion mutations and stop mutations) show more severe
phenotypes compared to those caused by non-inactivating
mutations (missense mutations) [5,8,9]. As well as a highly
accurate diagnosis, these genotype-phenotype correlation data
could provide prognostic information to help decide the strategy of
intervention with hearing, i.e., whether a child should receive
cochlear implantation or hearing aids. For the patients with severe
phenotypes who have GJB2 mutations, genetic information would
aid decision-making regarding cochlear implantation, because
their hearing loss is of cochlear origin and they therefore are good
candidates for implantation. In fact, cochlear implantation has
resulted in remarkable improvement in auditory skills and
development of speech production for patients with profound
hearing loss associated with GJB2 mutations [10].
In the SLC26A4 gene, 7 cases were homozygotes, 11 cases were
compound heterozygotes, and 7 cases had only one mutation
(Table 4). Of the 19 SLC26A4 mutations, 12 were not found in any
samples, but the remaining 7 mutations were all confirmed in
more than one patient. Especially, the p.H723R mutation was
found to be in high allele frequency (4.1%). Direct sequencing
identified novel mutations (c.1931+5G.A, p.S532I, p.R581S,
p.V659L) in the patients with a single mutation by Invader assay
and c.1219delCT mutation in a patient with EVA (Table 3).
As in our previous study [2], SLC26A4 mutations were found
only in the patients with EVA, suggesting a phenotype of hearing
loss with EVA can be a diagnostic indicator of this category of
disease.
Figure 2. Radiographic findings and detection rate. Detection rate was elevated when subjects were restricted to those with inner ear
anomaly or EVA. Combined direct sequence and invader screening enhanced the diagnostic rate but not the mutation detection rate.
doi:10.1371/journal.pone.0031276.g002
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istic of hearing loss associated with EVA [11,12] and the early
detection of SLC26A4 mutations enables prediction of these
clinical symptoms. Genetic testing is also useful in estimating
associated abnormalities (goiter), selection of appropriate habilita-
tion options, and better genetic counseling. In some cases, goiter is
evident during the teen years [12]. In this study, 8 patients had
hearing loss and goiter and 4 of them carried homozygous or
compound heterozygous SLC26A4 mutations.
In recessive mutations such as GJB2 and SLC26A4, detection of
two mutations in the paternal and maternal alleles is a hallmark. In
the present ‘‘two step’’ screening method Invader assay is first
performed followed by direct sequencing. As seen in Figs. 1 and 2,
most of the mutations were successfully detected by the first
Invader screening and the additional direct sequencing improved
the ‘‘diagnostic’’ rate. This is very important to find the first
mutation for identifying the responsible gene and the results
indicate this screening is technically efficient. Difficult cases of a
heterozygous state without a second mutation are also seen
[4,5,13,14]. As previously reported, in a substantial proportion of
patients our Invader techniques and additional direct sequencing
revealed only one mutant GJB2 or SLC26A4 allele causing
deafness by recessive pattern. We believe that there is one more
occult mutation somewhere because the frequency of heterozygous
patients was much higher than that of mutation frequency in the
control population. Another explanation may be the high
frequency of carriers in the population. But given the carrier
frequency in normal controls, the number of heterozygous
deafness cases was greater than would be expected. Second
mutations may be present in the same gene or genes in the same
chromosomal region. Recent statistical analysis has shown that
one allele mutation of GJB2 and SLC26A4 is more likely to be a
pathological status than a carrier status [15] and indeed, patients
with one SLC26A4 mutation are associated with EVA, therefore it
is strongly likely that there is a second mutation within this gene.
Another possibility is that mutations in the regulatory region may
be involved in phenotypic expression [16].
The m.1555A.G mutation in the mitochondrial 12SrRNA
gene, which was found in 5 4 subjects, was mainly found in those
with older onset age. This mutation has been reported to be
associated with aminoglycoside injection and found in 3% of the
patients who visited the outpatient clinic [17,18]. The current
findings are compatible with our previous report that this mutation
is a frequently encountered cause for postlingual deafness in
patients who received cochlear implantation [18]. This mutation
was also found in the congenital or early onset age group as well,
in line with our previous study [2]. It is likely that there is a
considerably large high-risk population worldwide and a rapid
screening method as well as careful counseling should be
established to prevent aminoglycoside-induced hearing loss in this
group.
The m.3243A.G mutation in the tRNA(Leu (UUR)) gene was
found in 6 patients in the older-onset group. This mutation was
first reported at a high frequently in the patients with clinical
manifestations of MELAS [19], and has also been found in
diabetes mellitus patients [20]. It is known to be commonly
associated with hearing loss patients (especially with diabetes
mellitus) [21]. The hearing loss is adult onset, symmetric high
frequency involved [22]. In this study, all 6 patients with this
mutation were associated with diabetes mellitus and progressive
hearing loss. Five patients had maternally inherited hearing loss
(the mother also had hearing loss), but one subject was a sporadic
case (the mother did not have hearing loss from the anamnestic
evaluation) and therefore is unlikely to be a mitochondrial
candidate from clinical evaluation. The present multigene
screening is also unexpectedly efficient for such atypical cases.
Heteroplasmy is one of the significant factors determining the
expression of mitochondrial disease. The Invader assay is
comparatively accurate at detecting the heteroplasmic rate [2],
and the present two patients with the 3243 mutation showed 3%
and 24% heteroplasmic rates.
In contrast to the three genes discussed above, mutations of the
COCH, KCNQ4, MYO7A, TECTA, CRYM, POU3F4 and EYA1
genes were not found in the present deaf subjects in line with our
previous study [2]. This is likely due to them being very rare and
usually independent mutations found in only one family. Although
analysis for these mutations should be performed to identify the
molecular nature of deafness as the first deafness screening step, a
different strategy may be necessary for screening for them.
In conclusion, the simultaneous examination of the multiple
deafness mutations by Invader assay followed by direct sequencing
if necessary, will enable us to detect deafness mutations in an
efficient and practical manner for clinical use. This screening
strategy will facilitate more precise clinical genetic diagnosis,
appropriate genetic counseling and proper medical management
for auditory disorders. Against this background, since 2008 the
Ministry of Health and Welfare of Japan has allowed this
screening to be performed as an advanced medical technology.
A Japanese summary of this article has been provided as
Supporting Information (Japanese summary S1).
Supporting Information
Japanese Summary S1 Simultaneous Screening of Mul-
tiple Mutations by Invader Assay. The present method of
simultaneous screening of multiple deafness mutations by Invader
assay followed by direct sequencing will enable us to detect
deafness mutations in an efficient and practical manner for clinical
use.
(PDF)
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